Shock NICE decision on AstraZeneca's olaparib
This article was originally published in Scrip
Executive Summary
In a surprise move, NICE – the HTA body for England and Wales – has issued a preliminary decision not to recommend AstraZeneca's PARP inhibitor Lynparza (olaparib), listing a series of worries. The drug was approved in December for women with relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer who have inherited BRCA mutations (BRCAm).